Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
extended-release methylphenidate
- Development stage
- Unknown
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- Small Molecules
- Administration
- Oral, Transdermal
01
Overview
Extended-Release Methylphenidate is an oral, long-acting formulation of the central nervous system (CNS) stimulant methylphenidate. It is widely approved and marketed under various brand names, including Concerta, Ritalin LA, and QuilliChew ER, for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The drug acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) by blocking the sodium-dependent dopamine transporter (DAT) and sodium-dependent norepinephrine transporter (NET), thereby increasing synaptic concentrations of these neurotransmitters in the prefrontal cortex and subcortical regions. In addition to its established indications, extended-release methylphenidate is being evaluated by St. Jude Children's Research Hospital in clinical trials (such as the STARS study) to address executive functioning deficits and attention problems in children and adolescents with sickle cell disease.
- Brand names
- Adhansia XRAptensio XRConcertaCotempla XR-ODTJornay PMMetadate CDMetadate ERMethylin ERQuilliChew ERQuillivant XRRelexxiiRitalin LARitalin SR
- Other names
- extended-release methylphenidateextended-release methylphenidate hydrochloridemethylphenidate ERmethylphenidate extended-releasemethylphenidate hydrochloride extended-releasemethylphenidate XR
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on extended-release methylphenidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on extended-release methylphenidate.